Troglitazone (TGZ), the first generation of TZDS, is a dual-agonist of PPAR-α and PPAR-γ, more strongly of the latter, which underlines its multi-functionalities in tackling inflammation on top of diabetes (126). This evidence concerns the gene PPARG and diabetes mellitus.